AstraZeneca CEO calls opening IRA drug price offer 'relatively encouraging' in first characterization of talks
The government’s first offer to AstraZeneca under the IRA’s drug price negotiations that began this month is “relatively encouraging,” CEO Pascal Soriot said Thursday, at least compared with the industry’s low expectations.
“What we’ve seen is relatively encouraging come back from CMS,” Soriot said during a press event with reporters timed with the UK company’s quarterly earnings results.
The word “relatively” may be a crucial caveat from Soriot, given that the drug industry had been bracing for a very low first offer. But the remarks are the first characterization by any drugmakers whose products are on the list for price negotiations with the US government. Drugmakers have almost entirely refrained from commenting, not wanting to be drawn into a public back-and-forth with a Biden administration that has made drug costs a major part of its agenda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.